In recent years, there has been a growing demand for DNA-based therapeutics, commonly known as gene therapy, to combat genetically-based pathologies. Because plasmid DNA have significantly different biophysical characteristics than proteins, their production can have a drastic impact on downstream purification unit operations. Join Dr. Stephen Palmieri and Dr. Jesse McCool of Lonza Biologics and Dr. Fred Blattner of Scarab Genomics as they take a detailed look at the challenges faced by pDNA manufacturers and how Lonzaâ€™s pDNA Production Platform addresses those challenges.
View this webcast to learn more about the advantages of the Lonza pDNA purification process, such as:
- Extremely high purity
- Shorter process time
- Low cost for resins
ThisÂ information is brought to you by Lonza